Personalized medicine: individualized care of cancer patients

Thompson, 2007, Commentary. The ubiquity of prostate cancer: echoes of the past, implications for the present: “What has been will be again, what has been done will be done again; there is nothing new under the sun.” ECCLESIASTES 1:9, Int J Epidemiol, 36, 287, 10.1093/ije/dym056 Sanda, 2008, Quality of life and satisfaction with outcome among prostate-cancer survivors, N Engl J Med, 358, 1250, 10.1056/NEJMoa074311 Petricoin Iii, 2002, Use of proteomic patterns in serum to identify ovarian cancer, Lancet, 359, 572, 10.1016/S0140-6736(02)07746-2 Bach, 2007, Computed tomography screening and lung cancer outcomes, JAMA, 297, 953, 10.1001/jama.297.9.953 Lissauer. Zwei Falle von Leucaeme Berliner Klin Wochnschr 1865;2:403–404. Papac, 2001, Origins of cancer therapy, Yale J Biol Med, 74, 391 Weston, 2004, Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine, J Proteome Res, 3, 179, 10.1021/pr0499693 Macmillan, 2007, In pursuit of personalized medicine, Reporter, Vanderbilt Medical Center's Weekly Paper Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA, 279, 1200, 10.1001/jama.279.15.1200 Goldstein, 2009, Common genetic variation and human traits, N Engl J Med, 360, 1696, 10.1056/NEJMp0806284 Penney, 2009, Evaluation of 8q24 and 17q risk loci and prostate cancer mortality, Clin Cancer Res, 15, 3223, 10.1158/1078-0432.CCR-08-2733 Freedman, 2006, Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men, Proc Natl Acad Sci U S A, 103, 14068, 10.1073/pnas.0605832103 Anderson, 2002, The human plasma proteome: history, character, and diagnostic prospects, Mol Cell Proteomics, 1, 845, 10.1074/mcp.R200007-MCP200 Ng, 1997, Frequent hypermethylation of p16 and p15 genes in multiple myeloma, Blood, 89, 2500, 10.1182/blood.V89.7.2500 Ely, 2005, Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma, Cancer Res, 65, 11345, 10.1158/0008-5472.CAN-05-2159 Bergsagel, 1989, Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?, Eur J Cancer Clin Oncol, 25, 159, 10.1016/0277-5379(89)90001-1 Kay, 2007, The role of prognostic factors in assessing “high-risk” subgroups of patients with chronic lymphocytic leukemia, Leukemia, 21, 1885, 10.1038/sj.leu.2404802 Wiestner, 2003, ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile, Blood, 101, 4944, 10.1182/blood-2002-10-3306 Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med, 2, 561, 10.1038/nm0596-561 Hughes, 2006, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, 108, 28, 10.1182/blood-2006-01-0092 Pritchard, 2006, HER2 and responsiveness of breast cancer to adjuvant chemotherapy, N Engl J Med, 354, 2103, 10.1056/NEJMoa054504 Bartlett, 2008, Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial, J Clin Oncol, 26, 5027, 10.1200/JCO.2007.14.6597 O'Malley, 2009, Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy, J Natl Cancer Inst, 101, 644, 10.1093/jnci/djp067 Burton, 2004, CD74 is expressed by multiple myeloma and is a promising target for therapy, Clin Cancer Res, 10, 6606, 10.1158/1078-0432.CCR-04-0182 Riker, 2007, Immunotherapy of melanoma: a critical review of current concepts and future strategies, Expert Opin Biol Ther, 7, 345, 10.1517/14712598.7.3.345 Baughn, 2006, A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6, Cancer Res, 66, 7661, 10.1158/0008-5472.CAN-06-1098